FRESCO-2: Fruquintinib in Patients with Refractory Metastatic CRC
Arvind N. Dasari, MD, MS, provides a comprehensive overview of the FRESCO-2 trial investigating fruquintinib in patients with refractory metastatic colorectal cancer.
Source: onclive.com